▼ -100.00% Downside Potential
This price target is based on 0 analysts offering 12 month price targets for The Medicines in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $84.90.
The current consensus among 0 contributing investment analysts is to n/a stock in The Medicines. This rating has held steady since November 2020, when it changed from a Hold consensus rating.
The Medicines Company, a biopharmaceutical company, focuses on developing therapeutics for the treatment of therosclerotic cardiovascular disease. The company is developing Inclisiran, an investigational RNA interference therapeutic that inhibits production of proprotein convertase subtilisin/kexin type 9, which controls LDL-cholesterol levels. It has collaboration agreement with Alnylam Pharmaceuticals, Inc. The Medicines Company was founded in 1996 and is headquartered in Parsippany, New Jersey.